Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06422689 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care

Study acronym: ANCHOR
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion moved earlier from Mar 31, 2027 to Feb 3, 2027v15
  2. Primary and study completion dates: Apr 29, 2026 to Mar 31, 2027 Enrollment target: 1507 to 1511v14 Show 1 more changeShow less
    • Enrollment target: 1507 to 1511
  3. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 1500 to confirmed 1507 · Study sites: 12 to 11v13 Show 2 more changesShow less
    • Enrollment target: estimated 1500 to confirmed 1507
    • Study sites: 12 to 11
  4. Re-verified, no change to tracked fieldsv12
  5. Enrollment target: 2000 to 1500 Study sites: 6 to 12 · Eligibility criteria shortened, about 5 wordsv11 Show 2 more changesShow less
    • Study sites: 6 to 12
    • Eligibility criteria shortened, about 5 words

    See this version in full on ClinicalTrials.gov ↗

Show 9 earlier versionsHide 9 earlier versions
  1. 2 versions Re-verified since Dec 9, 2024, no change to tracked fieldsv9-v10
  2. Study sites: 4 to 6v8
  3. Study sites: 3 to 4v7
  4. Re-verified, no change to tracked fieldsv6
  5. Study sites: 2 to 3v5
  6. Re-verified, no change to tracked fieldsv4
  7. Study sites: 3 to 2v3
  8. Study sites: 2 to 3v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
Asthma
927 trials monitored
See 32 trials at risk
ANCHOR is a prospective, phase IV, interventional, single-arm, open-label study of 1,500 adult participants with symptomatic asthma requiring the use of rescue therapy aimed to compare the asthma exacerbation rates before and after switching from albuterol or levalbuterol to albuterol plus budesonide inhalation aerosol as rescue therapy.
Trial Details
NCT Number NCT06422689
Lead Sponsor AstraZeneca
Collaborators: Premier HealthCare Solutions Inc.
Conditions Asthma
Enrollment 1,511 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov